eGov Monitor
7 Apr 2008
A*STAR’s Bioprocessing Technology Institute (BTI) has inked an agreement with Raven Biotechnologies, Inc., located in San Francisco, USA, for the development of a novel panel of stem cell antibodies or monoclonal antibodies. These antibodies are being hailed as the “new medicine of the future” as they are able to hit their designated targets precisely, making it easy and safe for therapeutic and diagnostic applications.
BTI’s partnership with Raven Biotechnologies will allow BTI to make use of Raven Biotechnologies’ proprietary whole cell immunization technology to develop monoclonal antibodies. This will allow BTI to further its research into stem cell purification and cell based diagnostics. Raven Biotechnologies, on the other hand, will use the monoclonal antibodies for screening cancer stem cell lines and cancer therapeutic development.
>>>> More
